

was measured using the specific cathepsin P substrate [Abz-FRF(4NO₂)-OH] and nonspecific substrate [Z-FR-AMC]. As the results, cathepsin P showed the significant preference for Abz-FRF(4NO₂)-OH. This purified human cathepsin P will be used in the screening of selectivity of proteinase inhibitors.

[This study was supported by a grant of the Korea Health 21 R&D Project, Republic of Korea (HMP-98-D-4-0028)]

[PC1-33] [10/20/2000 (Fri) 15:30 - 16:30 / [Hall B]]

Purification and Characterization of Polyphenol Oxidase from *Perillae Folium*

Kim YK^o, , Chae YZ

Seoul Metropolitan Government Research Institute of Public Health and Environment

Polyphenol oxidase (PPO) was purified from an triton X-114 extract of *Perillae Folium* by ammonium sulfate fractionation and chromatography on DEAE-cellulose. From chromatography on DEAE-cellulose two fractions with PPO activities were separated. Their fractions were examined by sodium dodesyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The result of electrophoresis molecular weight was 48Kd from first fraction and 37Kd from second fraction. PPO activity according to pH showed the similar value through broad pH range(4.0-9.0) at first fraction. While at second fraction optimum pH of PPO is 6.0. Substrate specificities of PPO showed the same result at the first and second fraction.

[PC1-34] [10/20/2000 (Fri) 15:30 - 16:30 / [Hall B]]

The Novel 40 kDa Cytosolic Phospholipase A₂ Is Implicated in Ca²⁺-dependent Arachidonic acid Release from Mammalian Red Blood Cells

Shin HS, Ryu CK¹, and Kim DK

College of Pharmacy, Chung-Ang University, ¹College of Pharmacy, Ewha Womens University, South Korea

Many recent lines of evidence show that red blood cells (RBC) can modify platelet pathophysiology through the release of arachidonic acid (AA) and eicosanoids formation including thromboxane A₂ and thus influence thrombosis and hemostasis. The release of AA is known to be a rate-limiting step for the production of eicosanoids and platelet-activating factor and occur by activation of phospholipase A₂ (PLA₂) as a major pathway. Recently we purified and characterized a novel 40 kDa form of cytosolic PLA₂, termed rPLA₂, from bovine RBC, which was further identified as an unknown protein in MALDI-TOF mass spectrometric analysis. To examine whether this rPLA₂ cause the Ca²⁺-dependent AA release from human and bovine RBCs, we developed a derivative of naphthaquinone, EA4, which inhibited rPLA₂ in a competitive pattern, and found this inhibitor also significantly decreased the Ca²⁺-dependent AA release from human and bovine RBCs metabolically labeled with [³H]AA. In contrast, methyl mercury and CNU-2 as cPLA₂ inhibitors and ETYA as sPLA₂ inhibitor did not change the Ca²⁺-dependent AA release. These results suggest that this rPLA₂ may be implicated in the Ca²⁺-dependent release of AA from mammalian RBCs.